Targeting EZH2 has broad antitumor effects in pre-clinical cancer models, and specific drugs (Tazemetostat, GSK2816126 and CPI-1205) targeting EZH2 are currently in clinical trials for lymphomas and advanced solid cancers [4]. This evidence concerns the gene EZH2 and cancer.